JHJarom Heijmans

Jarom Heijmans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jarom Heijmans has a total of 206 co-authors. Here are the top co-authors by number of shared publications:

  • Vanesa Muncan

    Affiliation Amsterdam UMC, University of Amsterdam, department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands

    5 shared publications
  • Erfan Nur

    Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    3 shared publications
  • Inger S Nijhof

    Department of Hematology, Amsterdam UMC, VU University , Amsterdam

    3 shared publications
  • Wouter L. Smit

    Affiliations Amsterdam UMC, University of Amsterdam, department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands

    3 shared publications
  • Abraham Goorhuis

    Department of Infectious Diseases, Amsterdam UMC Location University of Amsterdam , Amsterdam , The Netherlands

    2 shared publications
  • Arnon P Kater

    Department of Hematology, Amsterdam UMC Location University of Amsterdam , Amsterdam , The Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Potential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes

    by Charlotte J Teunis, Thomas J C Collins, Reindert F Oostveen, Annette E Neele, Menno de Winther, Nick S Nurmohamed, Jarom Heijmans, Maaike Winkelmeijer, Kim E Dzobo, Mark E Cooper, et al.

    Background and Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have anti-inflammatory effects in experimental studies, but their mechanism of action in humans remains unclear. This study characterized the cardiovascular–haematopoietic axis in individuals with T2D receiving semaglutide, as a potential mediator of GLP-1RA cardioprotective properties. Methods: In 16 individuals with T2D [63.2 ± 6.1 years, 37.5% female, weight 82.3 ± 15.3 kg, body mass index (BMI) 28.33 ± 3.5 kg/m2, LDL cholesterol 2.2 ± 0.9 mmol/L, glycated haemoglobin (HbA1c) 78.1 ± 13.1 mmol/mol, high-sensitivity C-reactive protein (hsCRP) 1.9 (1.2, 5.8) mg/L], blood and sternal bone marrow aspirates (subset, n = 14) were collected at baseline and after 6 months of semaglutide ≤2.0 mg weekly. Circulating monocytes and haematopoietic precursors were quantified by flow cytometry, plasma cytokines using an nELISA™ assay (Nomic Bio) and inflammatory macrophages in coronary arteries, bone marrow, and spleen by gallium-68–labelled DOTA-(Tyr3)-octreotate (68Ga-DOTATATE) positron emission tomography-computed tomography scans. Results: After 6 months of semaglutide, significant reductions in HbA1c (−21.1 mmol/mol, P < .0001), weight (−6.7 kg, P < .001), BMI (−2.5 kg/m2, P < .001), and hsCRP (−1.0 mg/L, P = .005) were observed. Circulating CD16+ monocytes were markedly lower (−18.8%, P = .034), with increased bone marrow retention correlating with weight loss, alongside reductions in interleukin-1 receptor antagonist, leptin, E-selectin, intercellular adhesion molecule-1 (ICAM-1), C-C motif chemokine ligand 2, C-C motif chemokine ligand 11, and C-X-C motif chemokine ligand 13. Gallium-68–labelled DOTA-(Tyr3)-octreotate PET-CT showed lower bone marrow uptake (−17.5%, P = .037), but not in spleen or coronary arteries. Conclusions: Semaglutide in T2D potentially reduces circulating inflammatory monocytes, increases bone marrow retention, and lowers markers of endothelial inflammation, with no reduction in coronary artery inflammatory macrophages. Semaglutide is associated with lower bone marrow 68Ga-DOTATATE uptake, which may relate to anti-inflammatory effects relevant to CVD risk.

  • Open Access

    Association between severe RSV pneumonia and invasive pulmonary aspergillosis

    by Jarom Heijmans, Josje Altenburg, Marije Bomers, Marcella Müller, Karin van Dijk

  • Open Access

    Reduced levels of mitochondrial ribosomal protein MRPL54 does not alter Apc related adenoma formation

    by Claudia N. Spaan, Eileen Daniels, Wouter L. Smit, Ruben J. de Boer, Joana Silva, Jacqueline L. M. Vermeulen, S. Meisner, Vanesa Muncan, Riekelt H. Houtkooper, Jarom Heijmans

    Reprogramming of energy metabolism is one of the hallmarks of cancer cells and mutations that modify wild type intestinal cells to colon carcinomas increases cellular energy expenditure. Mitochondria are the main site for ATP production in (cancer) cells and disrupting their function results in impaired tumor forming efficacy. The mitochondrial ribosomal proteins (MRPs) constitute the ribosome specifically in mitochondria, and as such are crucial for the translation process of the electron transport chain complex subunits. We hence aimed to explore the consequence of reduced MRP expression on adenomagensis and investigate this in a genetic mouse model with bodywide heterozygosity for Mrpl54 . We show that Mrpl54 heterozygosity does not alter adenoma formation, intestinal proliferation or apoptosis in a heterozygous Apc model. Furthermore, diminished Mrpl54 expression did not decrease stemness or global parameters of metabolism in colorectal cancer cell lines.

  • Open Access

    COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

    by Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg, Abraham Goorhuis, Mette D Hazenberg, Caroline E Rutten, Paul Den Tex, Elisabeth G E de Vries, Astrid A M van der Veldt, Jeanet M Kemmeren, et al.

    Background: In patients with hematologic malignancies, COVID-19 vaccine effectiveness is unknown and determinants of severe COVID-19 lack granularity. Methods: To identify determinants of SARS-CoV-2 infection outcome we conducted a population-based, nationwide cohort study, including all adult Dutch residents who tested positive for SARS-CoV-2 between 1 June 2020, and 31 March 2022. Individuals were classified as having a (history of) hematologic malignancy, solid malignancy, or no malignancies. Primary outcome was severe COVID-19, defined as COVID-19-related hospitalization or death following first SARS-CoV-2 infection. Results: Among 4 649 341 included individuals, those with hematologic malignancies were at highest risk of severe COVID-19. Vaccine effectiveness against severe COVID-19 in patients with hematologic malignancies was up to 74% (95% CI, 60% to 83%), depending on the SARS-CoV-2 variant period, the number of received vaccinations, and the time interval since vaccination. Risk of severe COVID-19 was highest for patients with recently diagnosed hematologic malignancies and declined over time, except for patients with chronic hematologic malignancies. Risk of severe COVID-19 tended to be higher in patients on tumor-specific treatment such as CD38 and CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors. Conclusions: COVID-19 vaccination lowered the risk of severe COVID-19 in SARS-CoV-2-infected patients with hematologic malignancies, although these patients remained at elevated risk compared with others. Determinants of severe COVID-19 included type of malignancy, time interval between malignancy diagnosis and SARS-CoV-2 infection, and treatment. These data can guide healthcare professionals in designing additional prevention and therapeutic strategies against respiratory virus infections for patients with hematologic malignancies.


  • Open Access

    Impact of an antimicrobial stewardship bundle on the outcome of high-risk neutropenic patients with fever: a pre-post study

    by Suzanne M E Kuijpers, Jara R de la Court, Jan M Prins, Rogier P Schade, Jarom Heijmans, Kim C E Sigaloff

    Background: Rapid antibiotic initiation is essential for managing potential infections following chemotherapy-induced neutropenia. However, excessive use of broad-spectrum antibiotics should be avoided. Implementing antimicrobial stewardship (AMS) in haematology units is challenging due to high infection-related risks, and data on interventions remain scarce. This study aimed to evaluate the safety of an AMS bundle on a haematology ward. Methods: A prospective cohort study was conducted at a tertiary care centre among patients with high-risk (≥7 days) neutropenia. The AMS bundle consisted of replacing empirical meropenem with ceftazidime, and shortening treatment duration to 2 days in case of defervescence and negative blood cultures. Data on ICU admission, all-cause mortality, antimicrobial use and microorganisms identified were compared with a (retrospective) pre-intervention cohort. Results: A total of 396 patients were included (206 pre-intervention, 190 post-intervention). Allogeneic stem cell transplantations increased from 21% pre-intervention to 37% post-intervention. There was no statistical difference in the adjusted composite endpoint of ICU admission and all-cause mortality [adjusted HR (aHR) 1.46; 95% CI, 0.76–2.81; P = 0.26]. Pre-intervention, meropenem was prescribed in 99% of patients, which shifted to ceftazidime in 78% post-intervention. Median antibiotic treatment duration decreased from 8.0 to 5.0 days (P < 0.001), and empirical antibiotic consumption decreased from 12 to 8 days of therapy per patient (P < 0.001). Bloodstream infections with Candida spp. decreased from 17 pre-intervention to 5 post-intervention (P = 0.03). Conclusions: The AMS bundle led to a shift towards narrower-spectrum antibiotics, and reduced treatment duration and overall antibiotic use without a significant impact on the primary safety outcome. The intervention was accompanied by a declining trend in candidaemia incidence.


  • Proteinuria Remission in Recurrent FSGS after Autologous Stem Cell Transplantation

    by W. Vincent T. Moolenaar, Rosanne H.N. Prins, Jarom Heijmans, Frederike J. Bemelman, Rik Westland

    An abstract is unavailable. This article is available as a PDF only.


  • ER stress and the unfolded protein response in gastrointestinal stem cells and carcinogenesis

    by Ruben J. de Boer, Jooske F. van Lidth de Jeude, Jarom Heijmans


  • Open Access

    Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis

    by Claudia N Spaan, Ruben J de Boer, Wouter L Smit, Jonathan Hm van der Meer, Manon van Roest, Jacqueline Lm Vermeulen, Pim J Koelink, Marte Aj Becker, Simei Go, Joana Silva, et al.

    In development of colorectal cancer, mutations inAPCare often followed by mutations in oncogeneKRAS. The latter changes cellular metabolism and is associated with the Warburg phenomenon. Glucose-regulated protein 78 (Grp78) is an important regulator of the protein-folding machinery, involved in processing and localization of transmembrane proteins. We hypothesize that targetingGrp78inApcandKras(AK)-mutant intestines interferes with the metabolic phenotype imposed byKrasmutations. In mice with intestinal epithelial mutations inApc,KrasG12Dand heterozygosity forGrp78(AK-Grp78HET) adenoma number and size is decreased compared withAK-Grp78WTmice. Organoids fromAK-Grp78WTmice exhibited a glycolysis metabolism which was completely rescued byGrp78heterozygosity. Expression and correct localization of glucose transporter GLUT1 was diminished inAK-Grp78HETcells. GLUT1 inhibition restrained the increased growth observed inAK-mutant organoids, whereasAK-Grp78HETorganoids were unaffected. We identifyGrp78as a critical factor inKras-mutated adenomagenesis. This can be attributed to a critical role forGrp78in GLUT1 expression and localization, targeting glycolysis and the Warburg effect.


  • Open Access

    Intestinal Apc‐inactivation induces HSP25 dependency

    by Sanne M van Neerven, Wouter L Smit, Milou S van Driel, Vaishali Kakkar, Nina E de Groot, Lisanne E Nijman, Clara C Elbers, Nicolas Léveillé, Jarom Heijmans, Louis Vermeulen

    The majority of colorectal cancers (CRCs) present with early mutations in tumor suppressor gene APC. APC mutations result in oncogenic activation of the Wnt pathway, which is associated with hyperproliferation, cytoskeletal remodeling, and a global increase in mRNA translation. To compensate for the increased biosynthetic demand, cancer cells critically depend on protein chaperones to maintain proteostasis, although their function in CRC remains largely unexplored. In order to investigate the role of molecular chaperones in driving CRC initiation, we captured the transcriptomic profiles of murine wild type and Apc‐mutant organoids during active transformation. We discovered a strong transcriptional upregulation of Hspb1, which encodes small heat shock protein 25 (HSP25). We reveal an indispensable role for HSP25 in facilitating Apc‐driven transformation, using both in vitro organoid cultures and mouse models, and demonstrate that chemical inhibition of HSP25 using brivudine reduces the development of premalignant adenomas. These findings uncover a hitherto unknown vulnerability in intestinal transformation that could be exploited for the development of chemopreventive strategies in high‐risk individuals.